Moreover, SOD2 levels could provide a cost-effective biomarker of response to the treatment in the first 2–3 months as a cell death BM, because these levels could identify whether the tumor is responding to this therapy, information which is not available through imaging techniques in this early phase of the treatment. The gene discussed is SOD2; the disease is neoplasm.